

Fibromyalgia - Pipeline Review, H1 2018

<https://marketpublishers.com/r/F932AF9EE55EN.html>

Date: January 2018

Pages: 68

Price: US\$ 2,000.00 (Single User License)

ID: F932AF9EE55EN

Abstracts

Fibromyalgia - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2018, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 2, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Fibromyalgia - Overview
- Fibromyalgia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Fibromyalgia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Fibromyalgia - Companies Involved in Therapeutics Development
- Aptinyx Inc
- Astellas Pharma Inc
- Daiichi Sankyo Co Ltd
- Innovative Med Concepts LLC
- Intec Pharma Ltd
- Jiangsu Hengrui Medicine Co Ltd
- KPI Therapeutics Inc
- Merck & Co Inc
- Pfizer Inc
- Prismic Pharmaceuticals Inc
- Switch Biotech LLC
- Fibromyalgia - Drug Profiles
- (cannabidiol + dronabinol) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (celecoxib + famciclovir) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AS-1069562 - Drug Profile
- Product Description

Mechanism Of Action

R&D Progress

ASP-0819 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-8062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirogabalin besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirtazapine ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-2925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palmidrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous

System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SWT-06101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VNP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibromyalgia - Dormant Projects

Fibromyalgia - Discontinued Products

Fibromyalgia - Product Development Milestones

Featured News & Press Releases

Aug 01, 2017: Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions

Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes

Mar 22, 2017: Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies

Mar 07, 2017: Journal of Pain Research Publishes Results of PRID-201, a successful Phase 2 Trial using IMC-1 for the Treatment of Fibromyalgia

Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national

Phase 3 Clinical Programs for Mirogabalin

Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study

Nov 27, 2012: Intellipharma Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin

Nov 19, 2012: Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia

Jul 23, 2012: Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica's Discontinuation Effects In Patients With Generalized Anxiety Disorder

Feb 02, 2009: UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Fibromyalgia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Fibromyalgia - Pipeline by Aptinyx Inc, H1 2018
Fibromyalgia - Pipeline by Astellas Pharma Inc, H1 2018
Fibromyalgia - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Fibromyalgia - Pipeline by Innovative Med Concepts LLC, H1 2018
Fibromyalgia - Pipeline by Intec Pharma Ltd, H1 2018
Fibromyalgia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Fibromyalgia - Pipeline by KPI Therapeutics Inc, H1 2018
Fibromyalgia - Pipeline by Merck & Co Inc, H1 2018
Fibromyalgia - Pipeline by Pfizer Inc, H1 2018
Fibromyalgia - Pipeline by Prismic Pharmaceuticals Inc, H1 2018
Fibromyalgia - Pipeline by Switch Biotech LLC, H1 2018
Fibromyalgia - Dormant Projects, H1 2018
Fibromyalgia - Dormant Projects, H1 2018 (Contd.1), H1 2018
Fibromyalgia - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fibromyalgia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Aptinyx Inc
Astellas Pharma Inc
Daiichi Sankyo Co Ltd
Innovative Med Concepts LLC
Intec Pharma Ltd
Jiangsu Hengrui Medicine Co Ltd
KPI Therapeutics Inc
Merck & Co Inc
Pfizer Inc
Prismic Pharmaceuticals Inc
Switch Biotech LLC

I would like to order

Product name: Fibromyalgia - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/F932AF9EE55EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F932AF9EE55EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970